|
1000
|
Abstract/Summary
|
-
<jats:p><jats:bold>Objective:</jats:bold> Few studies have quantified the influence of coronavirus disease 2019 (COVID-19) pandemic on medical providers. This is the first national study to investigate the impact of the pandemic on physicians practicing obstetrics and gynecology in China.</jats:p><jats:p><jats:bold>Methods:</jats:bold> A two-stage, stratified, cluster sampling method was performed based on the city categories (category 1, fewer than 10,000 beds; category 2, 10,000–30,000; and category 3, more than 30,000) and public hospital levels (primary, secondary, and tertiary). Physicians practicing obstetrics and gynecology reported the relevant changes in their general clinical activities and changes in the management of specific diseases or conditions occurring during the periods that they were most strongly affected. These changes were compared by municipal and hospital characteristics.</jats:p><jats:p><jats:bold>Results:</jats:bold> Questionnaires were collected from a representative sample of 11,806 physicians actively practicing obstetrics and gynecology in 779 hospitals from 157 cities of 31 provinces. Except emergency visits and online consultations, category 3 cities, tertiary hospitals and general hospitals had greater reductions in overall clinical activities than category 1 cities, primary hospitals and specialized hospitals (all adjusted <jats:italic>p</jats:italic> &lt; 0.05), respectively. The differences also existed in the management of specific diseases and conditions, especially for less urgent conditions, including cervical cancer screening, instructions regarding contraception and miscarriage, and assisted reproduction (all <jats:italic>p</jats:italic> &lt; 0.05).</jats:p><jats:p><jats:bold>Conclusions:</jats:bold> During the COVID-19 pandemic, the clinical obstetrics and gynecology activities in China markedly decreased, with significant differences across municipal and hospital characteristics.</jats:p><jats:p><jats:bold>Trial Registration:</jats:bold> This study was registered with <jats:ext-link>ClinicalTrials.gov</jats:ext-link> on July 27, 2020 (NCT04491201).</jats:p>
|
